Skip to main content
. 2021 Oct 27;126(1):109–119. doi: 10.1038/s41416-021-01579-4

Fig. 3. The deletion mutants of the KLF5 enhancer show decreased cancer stem-like properties.

Fig. 3

a Kaplan–Meier survival analysis of overall survival for 131 CRC clinical samples classified by KLF5 expression score. The high KLF5 expression group had poorer survival when compared with the low KLF5 expression group (P = 0.039). When the cut-off point was set at a median value of KLF5 mRNA, there were no significant differences in patients’ backgrounds between the high-KLF5 expression group (n = 65) and the low-KLF5 expression group (n = 66) (Supplementary Table S2). b The survival rate of parental cells and heterodeletion mutant clone #4 of the KLF5 enhancer after 5-FU and L-OHP treatment. *P < 0.05, **P < 0.01. c The number of spheres in parental cells and five heterodeletion mutants of the KLF5 enhancer. Five hundred cells were seeded, and the number was counted 3 weeks after seeding. The spheres larger than 50 µm were counted. The average number of five heterodeletion mutants is also shown. *P < 0.01. d The expression level of CSC-related genes in parental cells and five heterodeletion mutants of the KLF5 enhancer. The relative value is calculated by the expression level of the parental cells. The average value of five heterodeletion mutants is also shown. *P < 0.05, **P < 0.01. e The expression levels of CD44v9 and CD133 were analysed by flow cytometry in parental cells and five heterodeletion mutants of the KLF5 enhancer. The percentage of double-positive cells are shown.